Ruxolitinib Shows Consistent Results Across Vitiligo Groups

TOPLINE: Ruxolitinib cream was well tolerated, and the application of the cream led to clinically meaningful repigmentation in patients with vitiligo at 1 year, regardless of their baseline demographic and clinical characteristics. METHODOLOGY: This post hoc analysis included pooled data from two phase 3 studies (TRuE-V1 and TRuE-V2) in which adults and adolescents (aged ≥ …